Shay Shemesh, Chief Development & Operations Officer at Nuvectis Pharma, Inc. (NVCT), bought 1,113 shares at $6.32 ($7K) on 2024-05-10, disclosed to the SEC on 2024-05-13.
Open-market purchase of $7k NVCT by Chief Development & Operations Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| NVCT | BUY | 2022-12-22 | $4K | — | Filing → |
| NVCT | BUY | 2022-11-18 | $2K | — | Filing → |
| NVCT | BUY | 2022-09-27 | $2K | — | Filing → |